<DOC>
	<DOCNO>NCT00001004</DOCNO>
	<brief_summary>To study tolerance toxicity combination tumor necrosis factor ( TNF ) interferon gamma ( IFN-G ) single agent TNF IFN-G HIV infect patient . To selectively monitor immune system AIDS relate complex ( ARC ) patient receive either combination therapy TNF IFN-G alone . To obtain information effectiveness combination therapy TNF IFN-G alone HIV ARC patient . Recombinant TNF recombinant IFN-G show effective virus cause AIDS ARC laboratory study , may increase virus replication laboratory study . Previous study human show increase virus culture decrease measurement virus . Extensive preclinical data show TNF IFN-G effective together separately laboratory animal study . As single agent , TNF IFN-G modest effect HIV . Studies demonstrate TNF IFN-G , combination , inhibit HIV infection previously uninfected cell , also selectively induce destruction acutely infect target cell .</brief_summary>
	<brief_title>A Study Tumor Necrosis Factor Human Interferon-gamma Patients With AIDS Related Complex</brief_title>
	<detailed_description>Recombinant TNF recombinant IFN-G show effective virus cause AIDS ARC laboratory study , may increase virus replication laboratory study . Previous study human show increase virus culture decrease measurement virus . Extensive preclinical data show TNF IFN-G effective together separately laboratory animal study . As single agent , TNF IFN-G modest effect HIV . Studies demonstrate TNF IFN-G , combination , inhibit HIV infection previously uninfected cell , also selectively induce destruction acutely infect target cell . Patients ARC positive HIV antibody randomize receive one three treatment arm : ( 1 ) TNF alone intramuscular injection ( IM ) ; ( 2 ) IFN-G alone IM ; ( 3 ) TNF plus IFN-G . Patients receive IM injection 3 time weekly 4 month ( 16 week ) . Repeated physical examination laboratory test use monitor patient ' safety . Serial HIV culture core antigen assay employ obtain evidence antiviral activity serial T cell skin test use measure immunologic effect .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Necrosis</mesh_term>
	<mesh_term>AIDS-Related Complex</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-gamma</mesh_term>
	<criteria>Inclusion Criteria Patients primary diagnosis AIDS relate complex ( ARC ) include lymphadenopathy syndrome ( LAS ) , positive HIV antibody , minimum life expectancy 3 month , one follow symptom = &gt; 30 day : Fever . Night sweat . Fatigue . Oral thrush . Hairy leukoplakia . Diarrhea . Weight loss &lt; 10 percent . Patients must able sign write informed consent form , must obtain prior treatment . Concurrent Medication : Allowed : Acetaminophen temperature rise &gt; 38.5 degree C 650 mg mouth every 4 hour need basis . Severe rigor may treat ( prevent ) meperidine 50 mg IV need basis absence systolic hypotension &lt; 80 mm Hg . Exclusion Criteria Coexisting Condition : Patients follow exclude : Clinically significant cardiac disease New York Heart Association Class II , III , IV . Hemorrhagic diathesis ( include hemophilia ) active bleeding disorder ( e.g. , genitourinary , gastrointestinal ) . Clinically apparent vascular disease ( include prior history pulmonary embolus , deep venous thrombosis , peripheral arterial occlusive disease ) . Concurrent Medication : Excluded : Medications require treatment active cardiac disease include cardiac glycoside , antiarrhythmic antianginal agent . Anticoagulants . Thrombolytic agent . Nonsteroidal antiinflammatory drug . Ongoing therapy vasodilator . Aspirin . Corticosteroids . Antihistamines . Barbiturates . Excluded within 4 week study entry : Antiviral chemotherapy . Immunotherapy . Excluded within 12 week study entry : Suramin . Patients follow exclude : AIDSassociated opportunistic infection . Lipoprotein disorder . Hemophilia . Prior Medication : Excluded : Interferon gamma . Tumor necrosis factor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Tumor Necrosis Factor</keyword>
	<keyword>Interferon-gamma , Recombinant</keyword>
	<keyword>HIV Antigens</keyword>
	<keyword>Immunologic Surveillance</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
</DOC>